1
|
Li Y, Tang T, Xiao J, Wang J, Li B, Ma L, Xie S, Nie D. Clinical analysis of 11 cases of nocardiosis. Open Med (Wars) 2021; 16:610-617. [PMID: 33869782 PMCID: PMC8034244 DOI: 10.1515/med-2020-0196] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 02/05/2021] [Accepted: 02/24/2021] [Indexed: 11/15/2022] Open
Abstract
Nocardiosis is a rare, life-threatening, opportunistic, and suppurative infection. Its clinical manifestation lacks specificity, which makes early diagnosis difficult. A retrospective analysis of the clinical records of 11 patients with nocardiosis admitted to our hospital from January 2013 to November 2018 was conducted. All patients had at least one underlying disorder, such as an autoimmune disease (6/11), a blood malignancy (2/11), avascular necrosis of the femoral head (1/11), bronchiectasis (1/11), or pneumonia (1/11). The first-line treatment was trimethoprim-sulfamethoxazole (TMP-SMX); one or two additional antibiotics were given according to the drug-sensitive test. The median time from onset to treatment was 3 weeks (ranging from 1 to 9 weeks). The median duration of treatment after diagnosis was 20.5 weeks (ranging from 7 to 47 weeks). Eight patients were discharged and survived, and three patients died. This indicates that early use of TMP-SMX combined with sensitive antibiotics could improve the condition of patients and improve the cure rate (8/11). Clinically, it is necessary to consider the possibility of nocardiosis in patients with long-term use of immunosuppressants and poor response to treatment of common bacterial infections. Early diagnosis, timely treatment, and combination drug therapy are keys to improving the outcomes of patients with nocardiosis.
Collapse
Affiliation(s)
- Yiqing Li
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| | - Ting Tang
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| | - Jie Xiao
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| | - Jieyu Wang
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| | - Boqi Li
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| | - Liping Ma
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| | - Shuangfeng Xie
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| | - Danian Nie
- Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China
| |
Collapse
|